SEC Form 4 · accession 0001209191-19-007484
Denali Therapeutics Inc. · DNLI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Carole Ho
Officer — Chief Medical Officer
Period of report
Feb 1, 2019
Accepted (ET)
Feb 5, 2019 · 6:28 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001714899
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 1, 2019 | M | 5,775 | $5.28 | A | 5,775 | D | |
| Common StockF5 | Feb 1, 2019 | S | 5,775 | $18.64 | D | 0 | D | |
| Common Stock | Feb 4, 2019 | M | 730 | $5.28 | A | 730 | D | |
| Common Stock | Feb 4, 2019 | M | 3,139 | $5.28 | A | 3,869 | D | |
| Common StockF6 | Feb 4, 2019 | S | 3,100 | $18.49 | D | 769 | D | |
| Common StockF7 | Feb 4, 2019 | S | 769 | $19.11 | D | 0 | D | |
| Common Stock | Feb 5, 2019 | M | 7,856 | $5.28 | A | 7,856 | D | |
| Common StockF8 | Feb 5, 2019 | S | 7,856 | $18.83 | D | 0 | D | |
| Common StockF1 | holding | — | — | — | 46,875 | D | ||
| Common StockF2 | holding | — | — | — | 25,000 | I | See footnote | |
| Common StockF3 | holding | — | — | — | 142,615 | I | See footnote |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F9 | $5.28 | Feb 1, 2019 | M | 5,775 | D | — | Jul 1, 2026 | Common Stock | 5,775 | 96,610 | D |
| Stock Option (right to buy)F9 | $5.28 | Feb 4, 2019 | M | 730 | D | — | Jul 1, 2026 | Common Stock | 730 | 95,880 | D |
| Stock Option (right to buy)F10 | $5.28 | Feb 4, 2019 | M | 3,139 | D | — | Mar 7, 2027 | Common Stock | 3,139 | 137,486 | D |
| Stock Option (right to buy)F10 | $5.28 | Feb 5, 2019 | M | 7,856 | D | — | Mar 7, 2027 | Common Stock | 7,856 | 129,630 | D |
Explanation of responses
- F1The shares are held of record by Carole Ho and Rajat Rohatgi.
- F10Of the total 187,500 shares granted, 25% of the shares subject to the option vested on March 8, 2018 and an additional 1/48 of the shares vest monthly thereafter.
- F2The shares are held of record by the Rohatgi-Ho Irrevocable GST Trust, for which Reporting Person serves as trustee.
- F3The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee.
- F4The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.
- F5The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $18.39 to $18.93 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- F6The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $18.00 to $18.94 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- F7The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $19.04 to $19.15 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- F8The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $18.57 to $19.29 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- F9Of the total 125,000 shares granted, 25% of the shares subject to the option vested on July 2, 2017 and an additional 1/48 of the shares vest monthly thereafter.